Search

Displaying results 2761 - 2770 of 7687 in total
  1. Drug

    Trapidil

    go.drugbank.com/drugs/DB09283
    Experimental

    Trapidil, a platelet-derived growth factor antagonist, was originally developed as a vasodilator and anti-platelet agent and has been used to treat patients with ischemic coronary heart, liver, and kidney disease.

  2. Drug

    Mivacurium

    go.drugbank.com/drugs/DB01226
    ApprovedWithdrawn

    Mivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscul...

  3. Drug

    Tromethamine

    go.drugbank.com/drugs/DB03754
    ApprovedInvestigational

    as an alkalizer. … An organic amine proton acceptor.

  4. Drug

    Tribromsalan

    go.drugbank.com/drugs/DB20138
    ApprovedWithdrawn

    Tribromsalan has a monoisotopic molecular weight of 446.81 Da.

  5. Drug

    N-methylnicotinamide

    go.drugbank.com/drugs/DB08840
    Investigational

    N-methylnicotinamide is an experimental drug with no approved indication or marketed formulation.

  6. Drug

    Eflapegrastim

    go.drugbank.com/drugs/DB15001
    ApprovedInvestigational

    [L43135] In September 2022, eflapegrastim was approved by the US FDA as a prophylactic against infection, as manifested by febrile neutropenia, in patients receiving certain myelosuppressive anti-cancer … [A252320] It typically develops during the first cycle of chemotherapy and is associated with an increased risk of morbidity and mortality.

  7. Drug

    Relugolix

    go.drugbank.com/drugs/DB11853
    ApprovedInvestigational

    It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids,[A225816] and more recently by the United States' FDA in 2020, under the brand name … [A225926] In May 2021, the FDA approved the combination product made up of relugolix, [estradiol], and [norethindrone] under the market name Myfembree for the first once-daily treatment for the management

  8. Drug

    Bunamiodyl

    go.drugbank.com/drugs/DB04814
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to nephropathy.

  9. Drug

    Dantron

    go.drugbank.com/drugs/DB04816
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1998 due to genotoxicity.

    Mixtures: Regulex D CapInternational brands: Scatron D
  10. Drug

    Oxeladin

    go.drugbank.com/drugs/DB04822
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity.